v3.26.1
Segment Information - Results and Reconciliation of Operating Loss to Adjusted EBITDA (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 03, 2026
Apr. 03, 2026
Jul. 04, 2025
Jul. 03, 2026
Jul. 04, 2025
Dec. 31, 2025
Segment Reporting [Line Items]            
Net sales $ 582,782   $ 564,545 $ 1,171,933 $ 1,123,379  
Cost of Product and Service Sold 223,533   229,848 447,199 456,453  
Research and development expense 31,686   30,700 63,219 59,228  
Adjusted EBITDA (non-GAAP) 104,321   91,153 207,888 178,205  
Net Loss (GAAP) (1,036)   (36,548) (9,486) (92,253)  
Loss from discontinued operations, net of taxes 0   93 39 218  
Income tax expense 8,501   10,801 17,546 9,032  
Restructuring charges 4,859   920 7,567 4,829  
MDR and other costs 710   3,320 1,904 6,558  
Strategic transaction costs 1,408   13,450 12,440 25,504  
Stock-based compensation 8,902   8,668 17,652 16,075  
Depreciation and other amortization 29,468   28,588 60,917 58,212  
Amortization of acquired intangibles 41,561   42,962 83,465 84,774  
Purchase of royalty interest 0 $ 45,800 10,041 0 45,818  
Interest expense, net 8,038   9,294 17,207 18,482  
Other (income) expense, net 1,910   (436) (1,363) 956  
Adjusted EBITDA (non-GAAP) (6) 104,321   91,153 207,888 178,205  
Non-recurring charges 400   2,800 1,200 5,400  
Legal fees 300   400 700 1,100  
Business exit costs 200   300 400 800  
Assets 3,766,126     3,766,126   $ 3,834,737
Capital expenditures 43,895   44,369 96,699 87,631  
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold            
Segment Reporting [Line Items]            
Restructuring charges     200   300  
LimaCorporate S.p.A.            
Segment Reporting [Line Items]            
Strategic transaction costs 4,700   7,800 11,700 16,500  
Non-Lima Acquisitions            
Segment Reporting [Line Items]            
Strategic transaction costs     5,400 300 8,200  
Integration-related expense adjustment (3,500)          
Kico Knee Innovation Company Pty Limited            
Segment Reporting [Line Items]            
Gain on reversal 5,700          
Previously Reported            
Segment Reporting [Line Items]            
Adjusted EBITDA (non-GAAP)     97,200   196,300  
Adjusted EBITDA (non-GAAP) (6)     97,200   196,300  
Revision of Prior Period, Adjustment            
Segment Reporting [Line Items]            
Adjusted EBITDA (non-GAAP)     6,000   18,100  
Adjusted EBITDA (non-GAAP) (6)     6,000   18,100  
Prevention & Recovery            
Segment Reporting [Line Items]            
Net sales 288,248   290,570 560,266 563,154  
Cost of Product and Service Sold 124,094   131,336 249,851 260,100  
Research and development expense 7,706   9,669 15,453 18,910  
Other Cost and Expense, Operating 111,250   107,523 223,720 215,367  
Operating Costs and Expenses 243,050   248,528 489,024 494,377  
Depreciation 5,129   4,689 10,194 8,857  
Adjusted EBITDA (non-GAAP) 50,327   46,731 81,436 77,634  
Adjusted EBITDA (non-GAAP) (6) 50,327   46,731 81,436 77,634  
Assets 1,420,223     1,420,223   1,474,243
Capital expenditures 7,106   5,542 14,307 14,335  
Reconstructive            
Segment Reporting [Line Items]            
Net sales 294,534   273,975 611,667 560,225  
Cost of Product and Service Sold 98,873   97,750 196,208 195,024  
Research and development expense 23,980   21,031 47,766 40,318  
Other Cost and Expense, Operating 141,376   134,729 290,659 273,666  
Operating Costs and Expenses 264,229   253,510 534,633 509,008  
Depreciation 23,689   23,957 49,418 49,354  
Adjusted EBITDA (non-GAAP) 53,994   44,422 126,452 100,571  
Adjusted EBITDA (non-GAAP) (6) 53,994   44,422 126,452 100,571  
Assets 2,345,903     2,345,903   $ 2,360,494
Capital expenditures $ 36,789   38,827 $ 82,392 73,296  
Reconstructive | Previously Reported            
Segment Reporting [Line Items]            
Adjusted EBITDA (non-GAAP)     50,400   118,700  
Adjusted EBITDA (non-GAAP) (6)     $ 50,400   $ 118,700